Xiaodi Guo
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
-
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 6
-
- COVID-19 Clinical Research Studies 3
- SARS-CoV-2 and COVID-19 Research 2
- Co-authors
- Wendong Li (6 shared papers)Xiaoyan Ding (5 shared papers)Yanjun Shen (5 shared papers)Wei Li (4 shared papers)Jinglong Chen (4 shared papers)Wei Sun (4 shared papers)Ying Teng (3 shared papers)Xiaomin Liu (1 shared paper)
- Journals
- Worldviews on Evidence-Based Nursing (2 papers)Diabetes Metabolic Syndrome and Obesity (2 papers)Journal of Medical Virology (2 papers)European Journal of Clinical Pharmacology (1 paper)Human Vaccines & Immunotherapeutics (1 paper)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Xiaodi Guo
20 papers receiving 206 citations
Peers
Comparison fields: 5 of 40
- Hepatology 104
- Infectious Diseases 25
- Oncology 29
- Pathology and Forensic Medicine 16
- Epidemiology 30
Countries citing papers authored by Xiaodi Guo
This map shows the geographic impact of Xiaodi Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaodi Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaodi Guo more than expected).
Fields of papers citing papers by Xiaodi Guo
This network shows the impact of papers produced by Xiaodi Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaodi Guo. The network helps show where Xiaodi Guo may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaodi Guo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 103 | |
| 2 | 2020 | 18 | |
| 3 | 2020 | 15 | |
| 4 | 2020 | 13 | |
| 5 | 2020 | 12 | |
| 6 | 2021 | 12 | |
| 7 | 2023 | 7 | |
| 8 | 2021 | 7 | |
| 9 | 2023 | 5 | |
| 10 | 2024 | 3 | |
| 11 | 2022 | 2 | |
| 12 | 2023 | 2 | |
| 13 | 2024 | 2 | |
| 14 | 2017 | 1 | |
| 15 | 2023 | 1 | |
| 16 | 2020 | 1 | |
| 17 | 2025 | 1 | |
| 18 | 2024 | 1 | |
| 19 | CT-guided percutaneous chemical ablation combined with radiofrequency ablation for hepatocellular carcinomas in high-risk locations: lobaplatin vs. ethanol. | 2022 | 1 |
| 20 | 2013 | 1 |
About Xiaodi Guo
Xiaodi Guo is a scholar working on Hepatology, Infectious Diseases, Pulmonary and Respiratory Medicine, Epidemiology and Oncology, having authored 23 papers that have together received 208 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), COVID-19 Clinical Research Studies (3 papers), Ferroptosis and cancer prognosis (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Diabetes Management and Research (1 paper), Inflammatory Biomarkers in Disease Prognosis (1 paper) and Hyperglycemia and glycemic control in critically ill and hospitalized patients (1 paper). The work is most often cited by research in Hepatology (104 citations), Infectious Diseases (25 citations), Oncology (29 citations), Pathology and Forensic Medicine (16 citations) and Epidemiology (30 citations). Xiaodi Guo has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Wendong Li, Xiaoyan Ding, Yanjun Shen, Wei Li, Jinglong Chen, Wei Sun, Ying Teng, Xiaomin Liu, Linlin Zheng and Qiang Su. Their work appears in journals such as Worldviews on Evidence-Based Nursing, Diabetes Metabolic Syndrome and Obesity, Journal of Medical Virology, European Journal of Clinical Pharmacology and Human Vaccines & Immunotherapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.